Use of pharmacodynamic principles to inform β-lactam dosing: "S" does not always mean success.

Dose optimization is one of the key strategies for enhancing antimicrobial stewardship. There have been tremendous strides in our understanding of antibiotic exposure-response relationships over the past 25 years. For many antibiotics, the "pharmacodynamic" or the exposure variable associated with outcome has been identified. With advances in mathematical modeling, it is possible to apply our understanding of antimicrobial pharmacodynamics (PD) into clinical practice and design empirical regimens that have a high probability of achieving the PD target linked to effect. By optimizing antibiotic doses to achieve PD targets predictive of efficacy, clinicians can improve care and minimize drug toxicity. For β-lactams, the PD parameter most predictive of maximal bactericidal activity is the duration of time free drug concentrations remain above the minimum inhibitory concentration (MIC) during the dosing interval (fT > MIC). Unfortunately, the conventional intermittent β-lactam dosing schemes often used in practice have suboptimal PD profiles. Prolonging the infusion time of β-lactams is one method to maximize the probability of achieving concentrations in excess of the MIC for the majority of the dosing interval, especially against pathogens with elevated MIC values. Prolonged infusions of intravenous β-lactams are not only associated with improved probability of target attainment (PTA) profiles but offer possible cost savings and greater potential for reducing emergence of resistance relative to intermittent infusions.

[1]  G. Drusano,et al.  Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Nicolau,et al.  Length of Stay and Hospital Costs Associated with a Pharmacodynamic‐Based Clinical Pathway for Empiric Antibiotic Choice for Ventilator‐Associated Pneumonia , 2010, Pharmacotherapy.

[3]  D. Nicolau,et al.  Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. , 2010, Journal of critical care.

[4]  D. Paterson,et al.  A systematic review on clinical benefits of continuous administration of &bgr;-lactam antibiotics* , 2009, Critical care medicine.

[5]  M. Kinzig,et al.  Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia , 2011, Antimicrobial Agents and Chemotherapy.

[6]  F. Scaglione,et al.  Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. , 2008, International journal of antimicrobial agents.

[7]  Stephan Schmidt,et al.  PK/PD: new insights for antibacterial and antiviral applications. , 2008, Current opinion in pharmacology.

[8]  Qun Du,et al.  In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci , 2008, Antimicrobial Agents and Chemotherapy.

[9]  V. Tam,et al.  Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Aryun Kim,et al.  Optimal Dosing of Piperacillin‐Tazobactam for the Treatment of Pseudomonas aeruginosa Infections: Prolonged or Continuous Infusion? , 2007, Pharmacotherapy.

[11]  D. Nicolau,et al.  Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. , 2007, Diagnostic microbiology and infectious disease.

[12]  J. Burke,et al.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship , 2007 .

[13]  G. Drusano,et al.  Application of Antimicrobial Pharmacodynamic Concepts into Clinical Practice: Focus on β‐Lactam Antibiotics , 2006 .

[14]  Vincent H. Tam,et al.  Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.

[15]  B. Corrigan,et al.  How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  M. Kollef,et al.  Pseudomonas aeruginosa Bloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment , 2005, Antimicrobial Agents and Chemotherapy.

[17]  G. Drusano,et al.  Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation , 2004, Antimicrobial Agents and Chemotherapy.

[18]  G. Drusano How does a patient maximally benefit from anti-infective chemotherapy? , 2004, Clinical Infectious Diseases.

[19]  Ronald N. Jones,et al.  Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). , 2004, International journal of antimicrobial agents.

[20]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[21]  J. Rex,et al.  Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. , 2004, Diagnostic microbiology and infectious disease.

[22]  O. Cars,et al.  Postantibiotic, Postantibiotic Sub-MIC, and Subinhibitory Effects of PGE-9509924, Ciprofloxacin, and Levofloxacin , 2003, Antimicrobial Agents and Chemotherapy.

[23]  W. Craig,et al.  Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. , 1996, The Pediatric infectious disease journal.

[24]  W. Craig Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.

[25]  G. Drusano,et al.  Postantibiotic effect of imipenem on Pseudomonas aeruginosa , 1984, Antimicrobial Agents and Chemotherapy.

[26]  G. Rolinson,et al.  Effect of protein binding on antibiotic activity in vivo. , 1983, The Journal of antimicrobial chemotherapy.

[27]  P. McDonald,et al.  Enhancement of leukocyte activity against Escherichia coli after brief exposure to chloramphenicol , 1979, Antimicrobial Agents and Chemotherapy.

[28]  A. Novelli,et al.  Pharmacokinetic and Pharmacodynamic Parameters of Antimicrobials , 2009, Clinical pharmacokinetics.

[29]  A. Kumar Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy , 2008 .

[30]  Alan Forrest,et al.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  G. Drusano,et al.  Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. , 2006, Pharmacotherapy.

[32]  Ronald N. Jones,et al.  Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. , 2004, International journal of antimicrobial agents.

[33]  I. Odenholt Pharmacodynamic effects of subinhibitory antibiotic concentrations. , 2001, International journal of antimicrobial agents.

[34]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  O. Cars,et al.  The post-antibiotic sub-MIC effect in vitro and in vivo. , 1993, The Journal of antimicrobial chemotherapy.

[36]  M. Derriennic,et al.  Dirithromycin in the treatment of skin and skin structure infections. , 1993, The Journal of antimicrobial chemotherapy.

[37]  P. McDonald,et al.  Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. , 1981, Reviews of infectious diseases.